Loading
A phase 1/2 trial of ASP546C in gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Astellas Pharma Global Development, Inc., now recruiting.
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors is a phase 1/2 interventional study registered as NCT07488676 by Astellas Pharma Global Development, Inc., with 150 participants planned, started 2026-05-04 and due to reach its primary completion in 2029-07-31. Interventions recorded: ASP546C.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Claudin 18.2-positive gastric cancer, Metastatic pancreatic ductal adenocarcinoma, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Astellas, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Astellas, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/